Cholangiocarcinoma

Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma. Read More ›

Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control. Read More ›

The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer. Read More ›

The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study. Read More ›

Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies. Read More ›

Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection. Read More ›

In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner. Read More ›

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer. Read More ›

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements. Read More ›

The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers. Read More ›